Summary of actinic keratosis studies with imiquimod 5% cream

British Journal of Dermatology, Supplement

Volumn 149, Issue 66, 2003, Pages 37-39

  Tran, H ^a   Chen, K ^a   Shumack, S ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Care Centre   (Australia)

Author keywords

Clinical trials; Imiquimod; Solar keratosis

Indexed keywords

DICLOFENAC; FLUOROURACIL; HYDROXYACID; IMIQUIMOD; RETINOID;

ACTINIC KERATOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FOLLOW UP; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE;

EID: 0347320544     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0366-077x.2003.05629.x     Document Type: Conference Paper

References (14)

1. Marks R, Jolley D, Lectsas S, Foley P. The role of childhood exposure to sunlight in the development of solar keratoses and non-malignant skin cancer. Med J Aust 1990; 152: 62-6.
2. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma in the skin: a prospective study. Lancet 1988; 1: 795-7.
3. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment: a patient-oriented perspective. Arch Dermatol 1991; 127: 1029-31.
4. Shumack S, Robinson J, Kossard S et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138: 1165-71.
5. Geisse JK, Rich P, Pandya A et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
6. Sterry W, Ruzicka T, Herrera E et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
7. Marks R, Gebauer K, Shumack S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
8. Mackenzie-Wood A, de Kossard S, Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44: 462-70.
9. Hengge UR, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001; 137: 709-11.
10. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144: 1050-3.
11. Persaud A, Lebwohl M. Imiquimod cream in the treatment of actinic keratoses. J Am Acad Dermatol 2002; 47: S236-S239.
12. Stockfleth E, Ulrich C, Salasche SJ, Christophers E. A randomised, double-blind, vehicle-controlled study to assess imiquimod 5% cream for the treatment of actinic keratosis. Arch Dermatol 2002; 138: 1498-502.
13. Persaud AN, Shamuelova E, Sherer D et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002; 47: 553-6.
14. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002; 47: 571-7.